The androgen deprivation therapy (ADT), which has been specifically recommended for those with hormone-sensitive cases of the disease, is now the first oral treatment of its kind to be approved by the agency.
Prostate cancer is the most common cancer in men in the UK, with approximately 51,000 new cases diagnosed in England in 2022 alone.
ADTs work by reducing the level of androgen hormones, such as testosterone, which are needed by prostate cancer cells to grow…
